Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Episode 25 with actor and science advocate Alan Alda discussing communicating science
AB Science announces recruitment of first patient in phase 3 study of masitinib in progressive multiple sclerosis
Multi-parametric quantitative MRI of normal appearing white matter in multiple sclerosis, and the effect of disease activity on T2.
Episode 11 with Dr. Jack Antel on remyelination and on bedside-to-bench research
UCSF Seminar: "Imaging spinal cord gray matter atrophy in MS using SF-SIGMA. Is neuronal loss a key mediator of MS disability?"
[Neurophysiology in Guillain-Barré syndrome].
Hydrogen-rich water improves neurological functional recovery in experimental autoimmune encephalomyelitis mice.
Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis.
Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.
Hematopoietic stem cell transplantation for MS: extraordinary evidence still needed.
FOCIS 2013: Improving Human Health Through Immunology
CLIC1 regulates dendritic cell antigen processing and presentation by modulating phagosome acidification and proteolysis.
A monoclonal natural human IgM protects axons in the absence of remyelination.
Imaging in Pediatric Demyelinating and Inflammatory Diseases of Brain- Part 2.
Disease Modifying Therapies Modulate Cardiovascular Risk Factors in Multiple Sclerosis Patients.
CombiRx for MS not better than monotherapy
Detailed results from Biogen Idec and AbbVie's pivotal Phase 3 DECIDE study further define the efficacy and safety profile of ZINBRYTA™ (daclizumab high-yield process)
Normal volumes and microstructural integrity of deep gray matter structures in AQP4+ NMOSD.
In vivo and in vitro effects of multiple sclerosis immunomodulatory therapeutics on glutamatergic excitotoxicity.
Movement and structure of mitochondria in oligodendrocytes and their myelin sheaths.
Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
Optimal combination of FLAIR and T2-weighted MRI for improved lesion contrast in multiple sclerosis.
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.
Progressive Loss of Retinal Ganglion Cells and Axons in Nonoptic Neuritis Eyes in Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study.
New TECFIDERA® (dimethyl fumarate) data show sustained efficacy and long-term safety in a broad range of multiple sclerosis patients

Pages